| Similar Articles |
|---|
 |
Bio-IT World
September 2006
Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future.   |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
Chemistry World
June 21, 2006
Katharine Sanderson |
Peptide Agent Tracks Angiogenesis A molecular imaging agent that can track the progress of tumour growth is about to be trialled by GE Healthcare. |
Bio-IT World
March 10, 2003
Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. |
Bio-IT World
November 2006
Kevin Davies |
Jubilant Curries Favor with BioPharma The explosion of drug discovery and development operations in India is epitomized by the success of several companies. Quietly building on a decade of experience in computational and bio-IT fields, JBL is rapidly pushing into a suite of drug discovery and development activities. |
Bio-IT World
June 12, 2002
Morris R. Levitt |
A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity. |
Bio-IT World
November 2005 |
Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development. |
Bio-IT World
August 13, 2002
Russell & Dodge |
Necessary Liaisons: Making Standards Work Caroline Kovac, IBM Corp.'s general manager for life sciences, talks about the need for standards and her take on the troubled informatics world. |
The Motley Fool
April 13, 2004
Lita Epstein |
GE Bets on Health Care Closing a $9.5 billion deal for the U.K.'s Amersham assures a major role for GE Healthcare. |
Bio-IT World
March 8, 2005
Kevin Davies |
InforSense Approach to Data Sharing CEO Yike Guo discusses Shanghai's giant grid computing project to link scientists. |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
Bio-IT World
November 2006
Wendy Wolfson |
Oracle OpenWorld 2006: Pharma Stuck on Semantic Web At the recent Oracle OpenWorld conference, pharma executives offered evidence that some, at least, are using the semantic web to work smarter and lower drug development costs. |
Chemistry World
May 22, 2013 |
Notebooks go digital Electronic lab notebooks are changing the way many scientists interact with information. These notebooks, ELNs for short, capture experiment details and data that are fully searchable within and across experiments. |
Bio-IT World
June 17, 2004
Michael A. Greeley |
A Bet on Biomarkers Biomarkers are a hot topic among venture capitalists these days and while they are becoming increasingly important in drug discovery and delivery processes, there is great debate about the best business models for marketing the related tools. |
Bio-IT World
November 2005
Charles Firneno |
The Information Value Chain By looking at the evolution of pharma's information networks, strategies can be designed for IT solutions such as CRM, CTMS, AERSs, and business analytics software to deliver the highest possible value. |
Bio-IT World
January 12, 2004
Kevin Davies |
The Ultimate Platform Firm Greg Lucier on determinism in drug development at Invitrogen |
BusinessWeek
April 26, 2004
Brady & Capell |
GE Breaks The Mold To Spur Innovation Immelt is merging GE's health unit with Britain's Amersham -- and putting its chief in charge |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Bio-IT World
November 12, 2002
Debra Goldfarb |
Disruption --The Real Revolution What is the real promise of the genomic revolution? It is its power to unleash disruptive innovation -- technology that allows a new group of people with different skill sets to do things in a decentralized, less expensive way. |
Pharmaceutical Executive
April 1, 2007
Walter Armstrong |
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom. |
Bio-IT World
August 13, 2002
Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
Reactive Reports
Issue 57 |
Interview with Andrew Lemon With a background in Chemistry and a keen sense of business, this co-found of The Edge Software Consultancy helps global pharmaceutical companies increase the efficiency and productivity of their software tools. |
Bio-IT World
August 2005 |
Project Summaries Summaries of candidates for Bio-IT World's "Best Practices 2005" projects. |
Bio-IT World
November 14, 2003
Malorye Branca |
Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines. |
Bio-IT World
May 7, 2002
Malorye Branca |
In Silico Survivors Facing desperate times, bioinformatics companies revamp, refocus, or perish. |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
Bio-IT World
April 2007
Malorye Allison |
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? |
Bio-IT World
January 21, 2005
Jim Golden |
Top 10 Trends for 2005 Pharmacovigilance, compliance, outsourcing, and the CIO's role will be big this year. |
Bio-IT World
Dec 2006/Jan 2007
Allison Proffitt |
'An Unfortunate Storm': Tripos CEO Discusses Company Future Tripos announced that it has successfully sold its Discovery Informatics business to Vector Capital. Despite the company's difficulties, including a collapsed share price, president and CEO John McAllister is upbeat about the company's future. |
Bio-IT World
February 2007
Robert M. Frederickson |
Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform. |
Pharmaceutical Executive
September 1, 2008
Zhu Shen |
Unleash the Dragon Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital. |
Pharmaceutical Executive
June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? |
Bio-IT World
March 2007
Michael A. Greeley |
Can I Get Personal? VC's are back and seem very excited about the broader disease management and personalized medicine investment opportunities. |
Bio-IT World
December 10, 2002
Jim Hall |
21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives. |
The Motley Fool
May 21, 2010
Gregory T. Huang |
How Microsoft Will Become a Top Player in Health IT From the mouth of a top leader in the unit. |
Bio-IT World
June 2005
Nancy J. Kelley |
Building Centers of Excellence in Translational Medicine New approaches to drug development that will be more effective in translating research to patient delivery will require the design and construction of new facilities that foster new ways of working among larger, multidisciplinary, teams of scientists and medical professionals in biology, chemistry, physics, mathematics, engineering, computer science, and, of course, information technology. |
Pharmaceutical Executive
March 1, 2013
Keeling & Paz |
Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Bio-IT World
December 10, 2002
Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Pharmaceutical Executive
September 1, 2011
Richard Barker |
Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science. |
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler |
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? |
Bio-IT World
June 2006
Michael A. Greeley |
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
Chemistry World
August 23, 2012
Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
Bio-IT World
May 19, 2004
John Russell |
Informatics Black Boxes ... Not! Vertex's chief technical officer, discusses informatics' bad reputation, buying vs. building, open-source tools, and ROI on IT. |
Pharmaceutical Executive
September 1, 2005
Wolfgang Klietmann |
Thought Leader: (Eco)systemic Change The author discusses how various players within the healthcare system interact. |
